Quantcast

Latest Factor VII Stories

2011-11-08 06:47:57

(Ivanhoe Newswire) — A new drug commonly used to treat bleeding events in people with severe hemophilia can also be used to prevent such events from happening at all, according to this study. An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, examined the ability of FEIBA to prevent bleeds in people with severe hemophilia A with inhibitors. People with this condition...

2011-11-04 10:24:50

An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place. The study, the first to confirm the efficacy and safety of the drug FEIBA in bleed prevention is published in the Nov. 3, 2011 issue of the New England...

2011-10-24 12:02:07

Children's Hospital of Philadelphia study suggests strategy to bypass defect in hemophilia, may also benefit other bleeding disorders A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems. The researchers took the naturally occurring coagulation factor Xa (FXa), a protein active in blood clotting, and engineered it into a novel variant that safely...

2011-09-02 12:12:57

Trauma experts have criticized the BBC over a recent episode of Holby City that effectively advertised and promoted a drug that has no proven record of saving lives According to Dr Ian Roberts, Head of the World Health Organization Collaborating Centre on Injury Control at the London School of Hygiene & Tropical Medicine, the recent episode ("Big Lies, Small Lies") seriously misrepresents the scientific evidence. "In clinical trials, Factor VIIa (the drug presented in the program)...

2011-07-28 01:30:00

KYOTO, Japan, July 28, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia. The data were presented in a Scientific Session held in conjunction with the 23rd Congress of the International Society on Thrombosis...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related